NEW YORK, NY / ACCESSWIRE / September 19, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

TuSimple Holdings Inc. (NASDAQ:TSP)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/tusimple-holdings-class-action-loss-submission-form?prid=31913&wire=1
Lead Plaintiff Deadline: October 31, 2022
This lawsuit is on behalf of all persons who: (a) purchased or otherwise acquired TuSimple common stock pursuant and/or traceable to documents issued in connection with TuSimple's April 15, 2021 initial public offering; and/or (b) that purchased or otherwise acquired TuSimple securities between April 15, 2021 and August 1, 2022, both dates inclusive.

Allegations against TSP include that: (i) TuSimple's commitment to safety was significantly overstated and defendants concealed fundamental problems with the Company's technology; (ii) TuSimple was rushing the testing of its autonomous driving technology in order to deliver driverless trucks to the market ahead of its more safety-conscious competitors; (iii) there was a corporate culture within TuSimple that suppressed or ignored safety concerns in favor of unrealistically ambitious testing and delivery schedules; (iv) the aforementioned conduct made accidents involving the Company's autonomous driving technology more likely; (v) the aforementioned conduct invited enhanced regulatory scrutiny and investigatory action toward the Company; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Kohl's Corporation (NYSE:KSS)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/kohls-lawsuit-loss-submission-form?prid=31913&wire=1
Lead Plaintiff Deadline: November 1, 2022
Class Period: October 20, 2020 - May 19, 2022

Allegations against KSS include that: (i) Kohl's new strategic framework to 'drive top-line growth,' 'expand operating margin,' and become 'the most trusted retailer of choice for the active and casual lifestyle' (the 'Strategic Plan') was not well tailored to achieving the Company's stated goals; (ii) the defendants had likewise overstated the Company's success in executing its Strategic Plan; (iii) Kohl's had deficient disclosure controls and procedures, internal control over financial reporting, and corporate governance mechanisms; (iv) as a result, the Company's board of directors was able to and did withhold material information from shareholders about the state of Kohl's in the lead-up to the Company's annual meeting; (v) all the foregoing, once revealed, was likely to have a material negative impact on Kohl's financial condition and reputation; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Abbott Laboratories (NYSE:ABT)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/abbott-laboratories-lawsuit-loss-submission-form?prid=31913&wire=1
Lead Plaintiff Deadline: October 31, 2022
This lawsuit is on behalf of all persons or entities who purchased or otherwise acquired shares of Abbott common stock during the period from February 19, 2021, to June 8, 2022, inclusive.

According to the filed complaint, defendants touted the strength of Abbott's infant formula brands and their contribution to the Company's sales and revenue growth, despite knowing that the facility that manufactured those products was in flagrant violations of United States Food and Drug Administration ('FDA') health, safety, and manufacturing regulations. The complaint further alleges that defendants willfully or recklessly concealed these violations from investors, even though the violations put Abbott's infant formula business in dire jeopardy and left the Company exposed to a risk of severe regulatory action, including the recall of its products and closure of the Sturgis facility. Indeed, according to the complaint, defendants received direct warnings, communications, FDA inspection reports, and consumer complaints identifying in detail the safety and regulatory violations that were rampant at the Sturgis facility.

To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

SOURCE : The Law Offices of Vincent Wong